The US Supreme Court declined Monday to revive antitrust litigation over an alleged price-fixing scheme by Chinese exporters of vitamin C, a few years after the justices took a skeptical view of claims that the companies were just complying with Chinese law.
The high court said it won’t review a ruling by the US Court of Appeals for the Second Circuit, which has twice thrown out a $148 million verdict against the manufacturers, Hebei Welcome Pharmaceutical Co. and parent North China Pharmaceutical Group Corp.
In 2013, a jury found a number of China-based companies liable for coordinating the supply and prices of Vitamin C exported to the United States. The district court entered a trebled damages award of nearly $150 million. On appeal, the Second Circuit reversed, dismissing the case and holding that the district court was bound to defer to the explanation of Chinese law that was submitted in the lawsuit by the Ministry of Commerce of the People’s Republic of China, which said that Chinese law compelled the defendants to engage in the alleged conduct.
Later, the Supreme Court reversed the Second Circuit, concluding that it had afforded too much deference to the Chinese government. Animal Sci. Prods., Inc. v. Hebei Welcome Pharm. Co., 138 S. Ct. 1865 (2018). The Supreme Court remanded the case to the Second Circuit, instructing it to consider, but not to defer conclusively to, the Ministry’s statement.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI